Research Article

Involvement of Prohibitin Upregulation in Abrin-Triggered Apoptosis

Yu-Huei Liu,1,2,3 Konan Peck,4 and Jung-Yaw Lin1

1 Institute of Biochemistry and Molecular Biology, College of Medicine, National Taiwan University, Taipei 100, Taiwan
2 Graduate Institute of Integrated Medicine of Chinese Medicine, China Medical University, Taichung 404, Taiwan
3 Department of Medical Genetics and Medical Research, China Medical University Hospital, Taichung 404, Taiwan
4 Institute of Biomedical Sciences, Academia Sinica, Taipei 115, Taiwan

Correspondence should be addressed to Jung-Yaw Lin, linjy@ntu.edu.tw

Received 20 May 2011; Accepted 18 July 2011

1. Introduction

Abrin (ABR), a protein purified from the seeds of Abrus precatorius, induces apoptosis in various types of cancer cells. However, the detailed mechanism remains largely uncharacterized. By using a cDNA microarray platform, we determined that prohibitin (PHB), a tumor suppressor protein, is significantly upregulated in ABR-triggered apoptosis. ABR-induced upregulation of PHB is mediated by the stress-activated protein kinase/c-Jun NH2-terminal kinase (SAPK/JNK) pathway, as demonstrated by chemical inhibitors. In addition, ABR significantly induced the expression of Bax as well as the activation of caspase-3 and poly(ADP-ribose) polymerase (PARP) in Jurkat T cells, whereas the reduction of PHB by specific RNA interference delayed ABR-triggered apoptosis through the proapoptotic genes examined. Moreover, our results also indicated that nuclear translocation of the PHB-p53 complex may play a role in the transcription of Bax. Collectively, our data show that PHB plays a role in ABR-induced apoptosis, which may be helpful for the development of diagnostic or therapeutic agents.
subcellular localization; increased levels of PHB on the cell membrane facilitates tumorigenesis through its interaction with c-Raf induced by the Ras oncogene [28], whereas increased levels of PHB in the nucleus induces apoptosis by increasing the transcriptional activity of p53 and its translocation to the cytoplasm [29].

In order to understand the genetic basis of the apoptotic signaling exerted by ABR, a microarray platform was used to investigate the expression profiles of genes in Jurkat T cells after ABR exposure. Among the genes identified, PHB was significantly upregulated; however, it has yet to be determined whether PHB plays a role in ABR-triggered apoptosis. Here, we report that overexpression of PHB is involved in ABR-triggered Jurkat T cell apoptosis. Upregulation of PHB through the JNK/SAPK pathway activated the pro-apoptotic gene Bax via the accumulation and translocation of the PHB-p53 complex to the cytoplasm. The elucidation of the changes in gene expression and the cellular mechanisms of the response to ABR exposure may be helpful for the development of diagnostic or therapeutic agents.

2. Materials and Methods

2.1. Isolation of ABR. ABR was isolated from seeds of the red variety of A. precatorius using Sepharose 6B affinity column chromatography and purified as described in a previous study [30]. The purity and molecular weight of ABR protein were confirmed by Coomassie blue staining (data not shown). The stock protein solution was diluted with phosphate-buffered saline (PBS, pH 7.2) to a concentration of 100 μM.

2.2. Cells and Culture Conditions. The human Jurkat T leukemia cancer cell line was obtained from American Type Culture Collection and maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin. Cells were grown in suspension in a 5% CO2 humidified atmosphere at 37°C.

2.3. Cell Proliferation Assay. Cells were seeded in 96-well plates at a density of 5 × 10^3 cells per well and were treated with (various doses) or without ABR. At the indicated times, viable cells were analyzed by measuring the conversion of the tetrazolium salt 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate (WST-1) to formazan. The formazan dye produced by metabolically active cells was diluted with phosphate-buffered saline (PBS, pH 7.2) to a concentration of 100 μM.

2.4. The cDNA Microarray System. The gene expression patterns regulated by ABR were analyzed with a previously established cDNA microarray platform (9600 probes) [31]. The mRNA from cells with or without ABR treatment was extracted using an Oligotex-dT column (Qiagen). A 2 μg quantity of each mRNA sample was labeled with biotin or digoxigenin for membrane hybridization, dual-color detection, and image analysis as described previously [31].

2.5. Antibodies and Chemical Inhibitors. An antibody specific to PHB was purchased from Lab Vision Corporation. An antibody specific to p53 was obtained from Santa Cruz Biotechnology. Antibodies specific to cleaved-caspase-3, and cleaved-poly(ADP-ribose) polymerase (PARP) were purchased from Cell Signaling. Antibodies against Bax and actin were obtained from Chemicon. The chemical inhibitors PD 98059, SB 203580, and SP600125 were purchased from Sigma.

2.6. Immunoblotting. Total cell lysates were collected in lysis buffer (50 mM HEPES-KOH, pH 7.5, 1% Triton X-100, 150 mM NaCl, and protease inhibitor cocktail (Roche)). The extracts were centrifuged at 14000 rpm for 20 min, and then the clear supernatant was separated by using 10% SDS-PAGE. After transferred, the separated proteins to a polyvinylidene fluoride (PVDF) membrane (Immunobilon-P, 0.45 mm; Millipore, Billerica, Mass, USA) by using the NA-1512 semi-dry transfer apparatus (NIHON EIDO), the membranes were blocked with 5% skim milk in tris-buffered saline containing 1% Tween 20 (TBST, pH 7.4) at room temperature for 30 min and then incubated overnight at 4°C with primary antibodies. The membranes were washed 4 times with TBST for 10 min each at room temperature and incubated with HRP-conjugated secondary antibodies for 1 h at room temperature. The membranes were then washed 4 times with TBST. The proteins were visualized using the SuperSignal West Femto Chemiluminescent Kit (Thermo Scientific) and exposed to an X-ray film (Kodak). The Image J program (http://rsb.info.nih.gov/) was used for quantization the expression fold. For western blot analysis, the fold increase of the indicated proteins was determined by normalizing to corresponding actin expression. For IP-western analysis, the densitometry readings of the bands were normalized to control.

2.7. Enzyme-Linked Immunosorbent Assay (ELISA) for Phosphor MAPK Detection. Cells were treated with or without ABR after pretreating with the indicated inhibitors or vehicle (DMSO) alone. After the indicated period of time, cells were harvested and lysed as above. The PathScan MAP Kinase Multi-Target Sandwich ELISA kit was used to determine phosphor ERK, -p38, and -JNK/SAPK levels according to manufacturer’s instruction (Cell Signaling).

2.8. Short Interfering RNA. Short interfering RNAs (siRNAs) against PHB (sc-37629) and the negative control siRNA (sc-37007) were obtained from Santa Cruz Biotechnology. A total of 2 × 10^5 cells were plated in a 6-well plate for 24 h, and siRNA transfection was carried out using the Lipofectamine 2000 kit according to the manufacturer’s instructions (Invitrogen).
2.9. Terminal Deoxynucleotidyl Transferase-Catalyzed Deoxyuridine Triphosphate (dUTP)-Nick End Labeling (TUNEL) Method [15]. Apoptotic cell death was examined by TUNEL method as manufacturer's suggestion (Roche Molecular Biochemicals). Each sample with 1 × 10⁴ events was analyzed with a Becton-Dickinson FACSCalibur, and the distribution of cells was determined.

2.10. Chromatin Immunoprecipitation (ChIP) Assays. Cells treated with or without ABR for the indicated time periods were examined. After fixing the protein-DNA complex using formaldehyde (1% final concentration) at room temperature for 10 min, the reaction was stopped with glycerine. After washed and lysed the cells, the lysates were sonicated and centrifuged, and the supernatants were used for immunoprecipitation of Bax with PHB antibody or control IgG. Antibody-bound protein/DNA complexes were precipitated and eluted in 300 μL of elution buffer (1% SDS, 50 mM NaHCO₃). Cross-linking was reversed by heating at 65°C for 4 h. The DNA was resuspended in 200 μL of distilled water and treated with 30 μg of proteinase K at 37°C for 1 h, followed by phenol/chloroform extraction and ethanol precipitation. PCR was conducted using 100 ng of DNA as the template. The following PCR primers were used for the Bax promoter: forward primer 5′-CCGGAATTCAGACTGGA-3′ and reverse primer 5′-AGCTCTCCCGACGCAGAA-3′. Each band was quantitatively determined using the Image J program (http://rsb.info.nih.gov/). The densitometry readings of the bands were normalized to the input.

2.11. Statistical Analysis. SPSS 12.0 for Windows (SPSS Inc.) was used to analyze the data. A two-tailed paired-samples Student’s t-test was used for statistical analysis of the comparative data from the two groups. P-value <0.05 values were considered statistically significant.

3. Results

3.1. ABR Induces Upregulation of PHB in Human Jurkat T Cells. To evaluate the effect of ABR on leukemia cells in vitro, Jurkat T leukemia cells were exposed to 0.01–100 nM of ABR for 24 h. The cell viability was then determined by WST-1 assay. As shown in Figure 1(a), the growth of Jurkat T cells was reduced by ABR in a dose-dependent manner. The value of the 50% cytotoxic concentration (CC₅₀) for 24 h treatment was determined for the water fraction to be 0.32 ± 0.06 nM. The data are represented as mean ± SD from 3 independent experiments.

Microarray analysis was used to identify novel candidates that are differentially expressed after 1 nM ABR treatment for 3 h. A total of 128 genes, out of the 9600 probes tested, were significantly altered by >1.5-fold in response to ABR (P < 0.05). The top 10 significant up-/down-regulated genes are listed in Table 1, sorted by fold increase or decrease. PHB, a significantly upregulated gene with diverse cellular functions, was selected for further investigation. To explore the potential role of PHB in ABR-treated apoptosis, Jurkat T cells were first treated with ABR (0.1–10 nM). As shown in Figure 1(b), ABR significantly increased the expression of PHB protein after treatment for 9 h. Cells were further treated with 1 nM ABR for different time periods. An initial increase of PHB protein was observed at the 3 h time point and was sustained for up to 18 h after ABR treatment (Figure 1(c)). To determine whether PHB upregulation due to ABR is because of increased transcription or increased RNA stability, the RNA synthesis inhibitor actinomycin D or the protein synthesis inhibitor cyclohexamide was preincubated with cells for 1 h before ABR was added. The results show that not only actinomycin D but also cyclohexamide significantly diminished ABR-induced PHB upregulation (Figure 1(d)). This finding suggests that ABR-induced PHB upregulation requires de novo RNA synthesis.

3.2. ABR Upregulates PHB Expression through the SAPK/JNK Pathway. To explore which of the signaling pathways are required for ABR-induced upregulation of the PHB gene, several specific chemical inhibitors were used. The effect of these inhibitors was examined using an ELISA-based detection system (Figure 2(a)). Jurkat T cells were pretreated with PD98059 (PD, MEK inhibitor; 20 μM), SB203580 (SB, p38 MAPK inhibitor; 20 μM), or SP600125 (SP, JNK/SAPK inhibitor; 30 μM) for 1 h, followed by treatment with ABR for the time indicated; total protein was used to determine PHB expression. SP significantly reduced the ABR-induced PHB expression, whereas the 2 other kinase inhibitors PD and SB rarely affected on the upregulation of PHB (Figure 2(b)). These results suggest the possible involvement of JNK/SAPK, but not of ERK1/2 or p38 MAPK, in the regulation of PHB expression in Jurkat T cells treated with ABR.

3.3. PHB Is Involved in ABR-Induced Cell Apoptosis. Since ABR induced the expression of PHB, a tumor suppressor gene that may induce cell apoptosis by arresting the cell cycle at the G1/S phase, we focused on determining whether PHB participates in the apoptotic signaling triggered by ABR. Apoptosis induced by ABR (0.1 and 1 nM) was investigated using TUNEL method. As shown in Figure 3(a), group 1 and 2, the maximal apoptotic response was achieved 18 h after treating cells with ABR (77.7% apoptosis after 1 nM ABR treatment versus 38.5% apoptosis after 0.1 nM ABR treatment; P < 0.001). Although the specific PHB RNA interference (PHB siRNA) did significantly enhance cell apoptosis (PHB siRNA induces 22.8% apoptosis versus control siRNA induces 7.4% apoptosis, P < 0.001; Figure 3(a) groups 1 and 3), knockdown PHB reduced ABR-induced apoptosis (PHB siRNA reduced 1 nM ABR-induced apoptosis by 9.7%, P < 0.001, and PHB siRNA reduced 0.1 nM ABR-induced apoptosis by 16.6%, P < 0.001; Figure 3(a) groups 2 and 4). Apoptosis-related genes including Bax, caspase-3, and PARP were also examined. ABR significantly induced the expression of Bax (6.3-fold; P < 0.001) as well as the activation of caspase-3 and PARP in the Jurkat T cells (Figure 3(b), lanes 1 and 2). However, the activation was reduced when the PHB expression reduced (Figure 3(b),
Figure 1: Abrin (ABR) upregulates prohibitin (PHB) expression through transcriptional regulation in Jurkat T cells. (a) ABR-induced cytotoxic activity in a dose-dependent manner in Jurkat T cells after 24 h treatment. The data are represented as mean ± SD from 3 independent experiments. (b) ABR (0.1–10 nM) significantly increased the expression of PHB after treatment for 9 h. (c) ABR (1 nM)-induced upregulation of PHB in a time-dependent manner. (d) ABR-induced PHB upregulation requires de novo RNA synthesis.

3.4. Upregulation of Human Bax Expression through Translocation of the PHB-p53 Complex from the Cytoplasm to the Nucleus. The previously described results raised the possibility that PHB may be involved in the apoptotic processes triggered by ABR. On the other hand, increased levels of PHB in the nucleus may interact with the tumor suppressor protein p53 by which it exerts its apoptotic effect. Therefore, we attempted to determine whether there was an interaction between PHB and p53. As shown in Figure 4(a), PHB was translocated from the cytoplasm to the nucleus after ABR treatment for 6 h. Furthermore, a 1.3-, 1.4-, and 3.2-fold increase in p53 and a 1.1-, 1.3-, and 3.1-fold increase in the interaction with PHB were observed when cells were treated with ABR for 3, 6, and 9 h, respectively (Figure 4(b)). These results indicated that ABR may induce a physical interaction between PHB and p53 in the early stage of ABR-induced cell apoptosis. Since Bax is known to be one of the transcriptional regulation targets for PHB and p53, a ChIP assay was performed by using specific primers to amplify a potential p53-binding region in Bax. As shown in Figure 4(c), p53 was recruited to the promoter regions of Bax in a time-dependent manner. These results suggest that ABR induces the formation of the PHB-p53 complex in the nucleus, which enhances the transcriptional activity of p53 on Bax following apoptosis.

4. Discussion

Studies have shown that some proteins, including ABR, ricin, modeccin, diphtheria toxin, shiga toxin, and pseudomonas toxin, are apoptosis inducers [32–34]. Although ABR has been clearly identified as an inducer of apoptotic cell death by activating caspase-3 in several kinds of cancer cells [15, 35–38], the mechanisms of its involvement in cell apoptosis remain to be investigated. In this study, PHB is shown to be upregulated in a dose-dependent manner during ABR treatment and might play a potent role in ABR-triggered apoptosis by enhancing the activity and expression of p53. To the best of our knowledge, this is the first study to explain and demonstrate the role of PHB in ABR-induced apoptosis in human leukemia cells. The potential clinical applications of ABR may involve the enhancement of drug targeting as well as a decrease in side effects on noncancerous cells.

ABR is a RIP, which induces a shutdown of protein synthesis in target cells [33, 39]. However, previous reports also showed that the apoptosis-related protein Bax can be upregulated by ABR [40, 41]. Our results also indicated an overexpression of PHB and p53. One explanation is...
Table 1: Top 10 up-/downregulated genes changing in response to abrin exposure arranged by fold change. Gene common name, description, and gene ontology classification (where known) are listed.

| Unigene number | Common name | Description | Fold change | GO biological process | GO molecular function | GO cellular process |
|----------------|-------------|-------------|-------------|-----------------------|-----------------------|---------------------|
| Hs.326035      | EGR1        | Early growth response 1 | 12.9        | Transcription, DNA dependent | Transcription activator activity | Nucleus |
| Hs.502769      | SLC3A2      | Solute carrier family 3 (activators of dibasic and neutral amino acid transport), member 2 | 3.0         | Transmembrane transport | Catalytic activity | Plasma membrane |
| Hs.2178        | HIST2H2BE   | Histone cluster 2, H2bc | 2.5         | Nucleosome assembly | Binding to DNA and protein | Nucleus |
| Hs.82963       | GNRH1       | Gonadotropin-releasing hormone 1 (luteinizing-releasing hormone) | 2.4         | Multicellular organismal development | Hormone activity | Extracellular |
| Hs.467408      | TRIM28      | Tripartite motif-containing 28 | 2.3         | Negative regulation of cell proliferation, gene-specific transcription from RNA polymerase II promoter by competitive promoter binding; regulation of apoptosis; signal transduction | Transcription coactivator/corepressor activity | Nucleus |
| Hs.514303      | PHB         | Prohibitin | 2.3         | | Transcription activator/repressor activity | Cytoplasm, plasma membrane, mitochondria, nucleus |
| Hs.534404      | RPL10       | Ribosomal protein L10 | 2.2         | Translation | Structural constituent of ribosome | Cytosol |
| Hs.5120        | DYNLL1      | Dynein, light chain, LC8-type 1 | 2.2         | Induction of apoptosis | Motor activity | Cytosol |
| Hs.226390      | RRM2        | Ribonucleotide reductase M2 | 2.1         | DNA replication | Oxidoreductase activity | Cytosol |
| Hs.202207      | OSCP1       | Organic solute carrier partner 1 | 2.1         | Transport | | Plasma membrane |
| Hs.25524       | PTPN23      | Protein tyrosine phosphatase, non-receptor type 23 | 2.1         | Cell projection organization | Hydrolase activity | Cytosol |
| Unigene number | Common name | Description | Fold change | GO biological process | GO molecular function | GO cellular process |
|---------------|-------------|-------------|-------------|-----------------------|-----------------------|---------------------|
| Hs.725987     | TUBA1C      | Tubulin, alpha 1c | -1.8        | Cellular protein metabolic process | Structural molecule activity | Cytosol |
| Hs.535192     | EEF1A1      | Eukaryotic translation elongation factor 1 alpha 1 | -1.6        | Translation | Translation elongation factor activity | Cytosol |
| Hs.514581     | ACTG1       | Actin, gamma 1 | -1.6        | Cellular component movement | Protein binding | Cytosol |
| Hs.5662       | GNB2L1      | Guanine nucleotide-binding protein (G protein), beta polypeptide 2-like 1 | -1.5        | Positive regulation of apoptosis | Protein binding | Cytosol |
| Hs.534346     | RPS7        | Ribosomal protein S7 | -1.5        | Translation | Structural constituent of ribosome | Cytosol |
| Hs.433427     | RPS17       | Ribosomal protein S17 | -1.5        | Translation | Structural constituent of ribosome | Cytosol |
| Hs.5662       | GNB2L1      | Guanine nucleotide-binding protein (G protein), beta polypeptide 2-like 1 | -1.5        | Negative regulation of cell growth | Protein binding | Nucleus, cytosol |
| Hs.444467     | EEF1G       | Eukaryotic translation elongation factor 1 gamma | -1.5        | Translational elongation | Translation elongation factor activity | Cytosol |
| Hs.514581     | ACTG1       | Actin, gamma 1 | -1.5        | Cellular component movement | Structural constituent of cytoskeleton | Cytosol |
| Hs.509736     | HSP90AB1    | Heat shock protein 90kDa alpha (cytosolic), class B member 1 | -1.5        | Regulation of type I interferon-mediated signaling pathway | Unfolded protein binding | Cytosol |
Figure 2: The JNK/SAPK signaling pathway is required for abrin (ABR)-triggered upregulation of prohibitin (PHB). (a) Cells were treated with or without indicated inhibitors for 1 h before ABR treatment. Effects of PD98059 (PD; 20 μM), SB203580 (SB; 20 μM), or SP600125 (SP; 30 μM) on their target signaling molecules were shown. (b) Cells were pretreated with 20 μM PD, 20 μM SB, or 30 μM SP for 1 h before ABR treatment. After the indicated period of time, only SP significantly inhibited the upregulation of PHB by ABR as shown by western blot analysis.

Figure 3: Downregulation of prohibitin (PHB) delays abrin (ABR)-triggered cell apoptosis. (a) Downregulation of PHB expression with siRNA delays ABR-triggered cell apoptosis in Jurkat T cells. The cells were treated with 1 nM ABR for 18 h (n = 5). The average ± SD is shown from separate experiments. ***P < 0.001. (b) Downregulation of PHB inhibits expression of Bax and activation of caspase-3 and poly(ADP-ribose) polymerase (PARP) 9 h after ABR treatment as shown by western blot analysis.
Figure 4: Prohibitin (PHB) induces the transcriptional activity of p53, which promotes expression of Bax. (a) Abrin (ABR)-induced translocation of PHB from cytoplasm to nucleus. (b) ABR upregulates p53 (western blot) and promotes the interaction between PHB and p53 in cells (immunoprecipitated western blot). (c) Association of PHB with the promoter region of the p53-targeted gene Bax.

that cap-independent protein translation occurs in ABR-triggered apoptosis [42]. Hence, although PHB was first defined as a mitochondrial protein stabilizer [43], it was later shown to have diverse functions in a variety of processes including senescence, development, and tumor suppression [44]. In addition, PHB enhances the transcriptional activity of the tumor suppressor p53 via physical interaction [29, 45]. Our results are in agreement with earlier findings that PHB can interact with and upregulate p53 function during apoptosis [29]. It would, therefore, be interesting to determine the involvement of other coactivators in the PHB-p53 transcriptional activator complex upon ABR treatment.

Indeed, ABR may trigger cell apoptosis through its protein synthesis inhibition, ribotoxic stress, mitochondrial stress, PARP-induced NAD⁺ depletion, and ROS- and nuclease-induced DNA damage [46]. In addition, others and our previous works showed that ABR-induced apoptosis seems to occur either concomitantly with or before the inhibition of protein synthesis [15, 46]. Although we have not yet determined a correlation between the 3 different ABR-induced pathways (including depurination activity, AOP-1 interaction, and prohibitin upregulation), both our current study and previous results indicated that either overexpression of AOP-1 or blockade of PHB expression may significantly reduce apoptosis ($P < 0.05$ for each). ABR upregulates the expression of, but does not interact with, PHB. On the contrary, ABR interacts with AOP-1 without upregulating it (data not shown). Although AOP-1 and PHB are thought to share several conserved domains that are expected to play similar roles in normal cells, the reason why they display distinct functions upon ABR treatment is still unclear; this would be an interesting topic for further studies. In addition, it seems that the interaction of ABR with AOP-1 is independent of depurination activity, and whether the upregulation of PHB depends on depurination is open to further study. Only an efficient cellular transport system for the toxicity-free mutant (ABR A chain E164Q) would be free of intact protein contamination (e.g., the reassociation of the A chain to the B chain).

Moreover, our results here show that early growth response 1 (EGR1), a transcription factor that controls the early growth response and facilitates tissue healing, is significantly upregulated by ABR in leukemia cells. This result is in agreement with the response of lung epithelial cells to ricin [47], which may well serve as one of the markers of RIP-exerted toxicity. Ongoing studies are evaluating the
Figure 5: A model of abrin (ABR)-triggered apoptosis. ABR-induced apoptosis may occur through at least 3 pathways: first, inhibition of protein synthesis by its N-glycosidase activity; second, modulation of the function of mitochondria by specific interaction with antioxidant protein-1 (AOP-1); and third, interference with the transcription regulated by prohibitin (PHB). Repression of prohibitin attenuates ABR-triggered apoptosis via preventing the expression of BAX, cleaved-caspase 3, and cleaved-poly(ADP-ribose) polymerase (PARP). Once PHB is upregulated by ABR through the JNK/SAPK signaling pathway, the expression of proapoptotic gene Bax is turned on through the nuclear translocation and p53 interaction of PHB, by which activates the caspase cascade, and finally, apoptosis occurs.

In conclusion, we propose the model shown in Figure 5. ABR exhibits biological functions involving at least 3 pathways: translational inhibition, mitochondrial dysfunction, and transcriptional interfere through the upregulation of PHB. Since the downregulation of PHB significantly delays apoptosis induced by ABR, PHB could be employed in reducing the toxicity of immunotoxins and, hence, improve the efficiency of cancer chemotherapy.

Acknowledgments

This study was supported by Grants from the Committee on Chinese Medicine and Pharmacy (CCMP-96-RD-203-1) and the Department of Health (DOH97-TD-I-111-TM018, DOH98-TD-I-111-TM020), executive Yuan, Taiwan.

References

[1] J. Y. Lin, K. Y. Tserng, C. C. Chen, L. T. Lin, and T. C. Tung, “Abrin and ricin: new anti-tumour substances,” Nature, vol. 227, no. 5255, pp. 292–293, 1970.
[2] J. U. Baenziger and D. Fiete, “Structural determinants of Ricinus communis agglutinin and toxin specificity for oligosaccharides,” Journal of Biological Chemistry, vol. 254, no. 19, pp. 9795–9799, 1979.
[3] F. Stirpe, L. Barbieri, M. G. Battelli, M. Soria, and D. A. Lappi, “Ribosome-inactivating proteins from plants: present status and future prospects,” Nature Biotechnology, vol. 10, no. 4, pp. 405–412, 1992.
[4] S. J. Kaufman and A. McPherson, “Abrin and hurin: two new lymphocyte mitogens,” Cell, vol. 4, no. 3, pp. 263–268, 1975.
[5] V. P. Kamboj and B. N. Dhawan, “Research on plants for fertility regulation in India,” Journal of Ethnopharmacology, vol. 6, no. 2, pp. 191–226, 1982.
[6] J. Y. Lin, T. C. Lee, and T. C. Tung, “Inhibitory effects of four isoabrins on the growth of sarcoma 180 cells,” Cancer Research, vol. 42, no. 1, pp. 276–279, 1982.
[7] R. Hegde, T. K. Maiti, and S. K. Podder, “Purification and characterization of three toxins and two agglutinins from Abrus precatorius seed by using lactamyl-sepharose affinity chromatography,” Analytical Biochemistry, vol. 194, no. 1, pp. 101–109, 1991.
[8] S. Tripathi and T. K. Maiti, “Stimulation of murine macrophages by native and heat-denatured lectin from Abrus precatorius,” International Immunopharmacology, vol. 3, no. 3, pp. 375–381, 2003.

[9] V. Ramnath, G. Kuttan, and R. Kuttan, “Immunopotentiating activity of abrin, a lectin from Abrus precatorius Linn,” Indian Journal of Experimental Biology, vol. 40, no. 8, pp. 910–913, 2002.

[10] V. Ramnath, G. Kuttan, and R. Kuttan, “Antitumour effect of abrin on transplanted tumours in mice,” Indian Journal of Physiology and Pharmacology, vol. 46, no. 1, pp. 69–77, 2002.

[11] S. Tripathi and T. K. Maiti, “Immunomodulatory role of native and heat-denatured agglutinin from Abrus precatorius,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 2, pp. 451–462, 2005.

[12] A. Tilwari, N. P. Shukla, and U. D. Pathirissery, “Immunomodulatory activity of the aqueous extract of seeds of Abrus precatorius Linn (Jequirity) in mice,” Iranian Journal of Immunology, vol. 8, no. 2, pp. 96–103, 2011.

[13] K. J. Dickers, S. M. Bradberry, P. Rice, G. D. Griffiths, and J. A. Vale, “Abrin poisoning,” Toxicological Reviews, vol. 22, no. 3, pp. 137–142, 2003.

[14] L. N. L. Chan, J. S. Li, and S. Y. Liu, “Differential effects of abrin on normal and tumor cells,” Journal of Cellular Physiology, vol. 123, no. 1, pp. 132–138, 1985.

[15] S. F. Shih, Y. H. Wu, C. H. Hung, H. Y. Yang, and J. Y. Lin, “Abrin triggers cell death by inactivating a thiol-specific antioxidant protein,” Journal of Biological Chemistry, vol. 276, no. 24, pp. 21870–21877, 2001.

[16] W. Rizwani, M. Alexandrow, and S. Chellappan, “Prohibitin physically interacts with MCM proteins and inhibits mammalian DNA replication,” Cell Cycle, vol. 8, no. 10, pp. 1621–1629, 2009.

[17] S. Manjeshwar, D. E. Branan, M. R. Lerner, D. J. Brackett, and E. R. Jupe, “Tumor suppression by the probibitin gene 3’untranslated region RNA in human breast cancer,” Cancer Research, vol. 63, no. 17, pp. 5231–5236, 2003.

[18] T. F. Wu, H. Wu, Y. W. Wang et al., “Prohibitin in the pathogenesis of transitional cell bladder cancer,” Anticaner Research, vol. 27, no. 2, pp. 895–900, 2007.

[19] X. Kang, L. Zhang, J. Sun et al., “Prohibitin: a potential biomarker for tissue-based detection of gastric cancer,” Journal of Gastroenterology, vol. 43, no. 8, pp. 618–625, 2008.

[20] R. C. Gregory-Bass, M. Olatimwo, W. Xu et al., “Prohibitin silencing reverses stabilization of mitochondrial integrity and chemoresistance in ovarian cancer cells by increasing their sensitivity to apoptosis,” International Journal of Cancer, vol. 122, no. 9, pp. 1923–1930, 2008.

[21] R. Ummann, H. Junker, U. Zimmermann et al., “Prohibitin identified by proteomic analysis of prostate biopsies distinguishes hyperplasia and cancer,” Cancer Letters, vol. 266, no. 2, pp. 171–185, 2008.

[22] H. Z. Ren, J. S. Wang, G. Q. Pan et al., “Comparative proteomic analysis of β-catenin-mediated malignant progression of esophageal squamous cell carcinoma,” Diseases of the Esophagus, vol. 23, no. 2, pp. 175–184, 2010.

[23] M. J. Nuell, D. A. Stewart, L. Walker et al., “Prohibitin, an evolutionarily conserved intracellular protein that blocks DNA synthesis in normal fibroblasts and HeLa cells,” Molecular and Cellular Biology, vol. 11, no. 3, pp. 1372–1381, 1991.

[24] T. Sato, H. Saito, J. Swensen et al., “The human prohibitin gene located on chromosome 17q21 is mutated in sporadic breast cancer,” Cancer Research, vol. 52, no. 6, pp. 1643–1646, 1992.

[25] R. T. Dell’Orco, J. K. McClung, E. R. Jupe, and X. T. Liu, “Prohibitin and the senescent phenotype,” Experimental Gerontology, vol. 31, no. 1-2, pp. 245–252, 1996.

[26] E. Ikonen, K. Fiedler, R. G. Parton, and K. Simons, “Prohibitin, an antiproliferative protein, is localized to mitochondria,” FEBS Letters, vol. 358, no. 3, pp. 273–277, 1995.

[27] E. R. Jupe, T. S. Liu, J. L. Kiehlbauch, J. K. McClung, and R. T. Dell’Orco, “Prohibitin in breast cancer cell lines: loss of antiproliferative activity is linked to 3’ untranslated region mutations,” Cell Growth and Differentiation, vol. 7, no. 7, pp. 871–878, 1996.

[28] K. Rajalingam and T. Rudel, “Ras-Raf signaling needs prohibitin,” Cell Cycle, vol. 4, no. 11, pp. 1503–1505, 2005.

[29] G. Fusaro, P. Dasgupta, S. Rastogi, B. Joshi, and S. Chellappan, “Prohibitin induces the transcriptional activity of p53 and is exported from the nucleus upon apoptotic signaling,” Journal of Biological Chemistry, vol. 278, no. 48, pp. 47853–47861, 2003.

[30] P. P. Knowles and P. E. Thorpe, “Purification of immunotoxins containing ricin A-chain and abrin A-chain using blue sepharose CL-6B,” Analytical Biochemistry, vol. 160, no. 2, pp. 440–443, 1987.

[31] J. J. W. Chen, R. Wu, P. C. Yang et al., “Profiling expression patterns and isolating differentially expressed genes by cDNA microarray system with colorimetry detection,” Genomics, vol. 51, no. 3, pp. 313–324, 1998.

[32] N. Komatsu, T. Oda, and T. Muramatsu, “Involvement of both caspase-like proteases and serine proteases in apoptotic cell death induced by ricin, modeccin, diphtheria toxin, and pseudomonas toxin,” Journal of Biochemistry, vol. 124, no. 5, pp. 1038–1044, 1998.

[33] K. Sandvig and B. van Deurs, “Toxin-induced cell lysis: protection by 3-methyladenine and cycloheximide,” Experimental Cell Research, vol. 200, no. 2, pp. 253–262, 1992.

[34] S. K. Kochi and R. J. Collier, “DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis,” Experimental Cell Research, vol. 208, no. 1, pp. 296–302, 1993.

[35] S. Narayanan, A. Surolia, and A. A. Karande, “Ribosome-inactivating protein and apoptosis: abrin causes cell death via mitochondrial pathway in Jurkat cells,” Biochemical Journal, vol. 377, no. 1, pp. 233–240, 2004.

[36] H. Ohba, S. Moriwaki, R. Bakalova, S. Yasuda, and N. Yamasaki, “Plant-derived abrin-a induces apoptosis in cultured leukemia cell lines by different mechanisms,” Toxicology and Applied Pharmacology, vol. 195, no. 2, pp. 182–193, 2004.

[37] X. Qu and L. Qing, “Abrin induces HeLa cell apoptosis by cytochrome c release and caspase activation,” Journal of Biochemistry and Molecular Biology, vol. 37, no. 4, pp. 445–453, 2004.

[38] V. Ramnath, P. S. Rekha, G. Kuttan, and R. Kuttan, “Regulation of Caspase-3 and Bcl-2 expression in Dalton’s lymphoma ascites cells by abrin,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 2, pp. 233–238, 2009.

[39] G. D. Griffiths, M. D. Leek, and D. J. Gee, “The toxic plant proteins ricin and abrin induce apoptotic changes in mammalian lymphoid tissues and intestine,” Journal of Pathology, vol. 151, no. 3, pp. 221–229, 1987.

[40] S. K. Bhutia, S. K. Mallick, S. Maiti, D. Mishra, and T. K. Maiti, “Abrus abrin derived peptides induce apoptosis by targeting mitochondria in HeLa cells,” Cell Biology International, vol. 33, no. 7, pp. 720–727, 2009.
[41] S. K. Bhutia, S. K. Mallick, S. Maiti, and T. K. Maiti, “Inhibitory effect of Abrus abrin-derived peptide fraction against Dalton’s lymphoma ascites model,” *Phytomedicine*, vol. 16, no. 4, pp. 377–385, 2009.

[42] T. E. Graber and M. Holcik, “Cap-independent regulation of gene expression in apoptosis,” *Molecular Biosystems*, vol. 3, no. 12, pp. 825–834, 2007.

[43] X. Wang, X. Zuo, B. Kucejova, and X. J. Chen, “Reduced cytosolic protein synthesis suppresses mitochondrial degeneration,” *Nature Cell Biology*, vol. 10, no. 9, pp. 1090–1097, 2008.

[44] J. K. McClung, E. R. Jupe, X. T. Liu, and R. T. Dell’Orco, “Prohibitin: potential role in senescence, development, and tumor suppression,” *Experimental Gerontology*, vol. 30, no. 2, pp. 99–124, 1995.

[45] S. Rastogi, B. Joshi, P. Dasgupta, M. Morris, K. Wright, and S. Chellappan, “Prohibitin facilitates cellular senescence by recruiting specific corepressors to inhibit E2F target genes,” *Molecular and Cellular Biology*, vol. 26, no. 11, pp. 4161–4171, 2006.

[46] S. Narayanan, K. Surendranath, N. Bora, A. Surolia, and A. A. Karande, “Ribosome inactivating proteins and apoptosis,” *FEBS Letters*, vol. 579, no. 6, pp. 1324–1331, 2005.

[47] L. DaSilva, D. Cote, C. Roy et al., “Pulmonary gene expression profiling of inhaled ricin,” *Toxicol*, vol. 41, no. 7, pp. 813–822, 2003.

[48] K. Surendranath and A. A. Karande, “A neutralizing antibody to the A chain of abrin inhibits abrin toxicity both in vitro and in vivo,” *Clinical and Vaccine Immunology*, vol. 15, no. 5, pp. 737–743, 2008.

[49] J. Tang, T. Yu, L. Guo, J. Xie, N. Shao, and Z. He, “In vitro selection of DNA aptamer against abrin toxin and aptamer-based abrin direct detection,” *Biosensors and Bioelectronics*, vol. 22, no. 11, pp. 2456–2463, 2007.